Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based Cohort

Frøslie, Kathrine Frey; Jahnsen, Jørgen; Moum, Bjørn; Vatn, Morten H.

doi:10.1053/j.gastro.2007.05.051

Cited by 1,028 publications

(654 citation statements)

References 10 publications

Supporting

Mentioning

610

Contrasting

Unclassified

Order By: Relevance

“…In conducting longitudinal research in patients with IBD, researchers need to choose the disease measures based on what is critical for the research. Consideration of endoscopic inflammation and healing as an important therapeutic target has only recently emerged as a potentially important goal 38 . If this is the goal in a longitudinal study then endoscopy or imaging should be incorporated.…”

Section: Discussionmentioning

confidence: 99%

The Manitoba IBD Index: Evidence for a New and Simple Indicator of IBD Activity

et al. 2009

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The Manitoba IBD Index: Evidence for a New and Simple Indicator of IBD Activity

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Many clinical studies have shown that achievement of mucosal healing in UC or CD patients predicts both long-term remission and low risk for surgery [102,103]. Conversely, failure to achieve mucosal healing may predict a poor prognosis [104].…”

Section: Iecs As Target Cells For the Treatment Of Ibdmentioning

confidence: 99%

Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease

2015

View full text Add to dashboard Cite

In the past decades, continuous effort has been paid to deeply understanding the pathophysiology of inflammatory bowel diseases (IBD), such as ulcerative colitis or Crohn's disease. As the disease typically arises as chronic inflammation of the gastrointestinal mucosa, research has been focused on how such an uncontrolled, deleterious immune response may arise and persist in a certain cohort of patients. Based on those immunologic analyses, the establishment of anti-TNF-a therapy, and the following series of biologic agents achieved great success and dramatically changed the therapeutic strategy of IBD patients. However, to guarantee long-term remission of the disease, the therapeutic standard has been raised to achieve ''mucosal healing'', which requires complete repair of the gastrointestinal mucosa. Recent studies have revealed the unexpected importance of epithelial cells in the pathophysiology of IBD. The general barrier function as well as the cell lineage-specific functions have been deeply attributed to the development of chronic intestinal inflammation. Also, the groundbreaking establishment of the in vitro intestinal stem cell culture system has opened up a way of developing stem cell transplantation therapy to treat otherwise refractory ulcers that may persist in IBD patients. In this review, we would like to focus on the role of epithelial cells in the pathophysiology of IBD, and also give a perspective to the upcoming development of regenerative therapies that may become one of the therapeutic choices to achieve mucosal healing in refractory patients of IBD.

show abstract

“…Clinical trials of infliximab in ulcerative colitis demonstrated efficacy for inducing grossly visible mucosal healing, termed endoscopic remission [15]. Later studies showed that endoscopic remission was associated with superior clinical outcomes [37,38]. At present, objective outcomes are increasingly being used to support the efficacy of new therapies [39].…”

Section: Development Of Infliximabmentioning

confidence: 99%

The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions

Sofia

Rubin

2017

Dig Dis Sci

View full text Add to dashboard Cite

The development of therapeutic antibodies represents a revolutionary change in medical therapy for digestive diseases. Beginning with the initial studies that confirmed the pathogenicity of cytokines in inflammatory bowel disease, the development and application of therapeutic antibodies brought challenges and insights into their potential and optimal use. Infliximab was the first biological drug approved for use in Crohn's disease and ulcerative colitis. The lessons learned from infliximab include the importance of immunogenicity and the influence of pharmacokinetics on disease response and outcomes. Building on this foundation, other therapeutic antibodies achieved approval for inflammatory bowel disease and many more are in development for several digestive diseases. In this review, we reflect on the history of therapeutic antibodies and discuss current practice and future directions for the field.

show abstract

Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based Cohort

Cited by 1,028 publications

References 10 publications

The Manitoba IBD Index: Evidence for a New and Simple Indicator of IBD Activity

The Manitoba IBD Index: Evidence for a New and Simple Indicator of IBD Activity

Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease

The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions

Contact Info

Product

Resources

About